GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Probi AB (OSTO:PROB) » Definitions » Notes Receivable

Probi AB (OSTO:PROB) Notes Receivable : kr0.0 Mil (As of Mar. 2024)


View and export this data going back to 1998. Start your Free Trial

What is Probi AB Notes Receivable?

Probi AB's Notes Receivable for the quarter that ended in Mar. 2024 was kr0.0 Mil.


Probi AB Notes Receivable Historical Data

The historical data trend for Probi AB's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Probi AB Notes Receivable Chart

Probi AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Probi AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Probi AB Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Probi AB Notes Receivable Related Terms

Thank you for viewing the detailed overview of Probi AB's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Probi AB (OSTO:PROB) Business Description

Traded in Other Exchanges
Address
Ideongatan 1 A, Lund, SWE, SE-223 70
Probi AB is engaged in probiotic research and development, manufacturing and sales of effective and well-documented probiotics. The company's research relates to living microorganisms with scientific health benefits. The main fields of research are gut health, immune system and nutrient absorption, iron absorption, bone health and stress and recovery. It operates in Consumer Healthcare (CHC) and Functional Food (FF). The company operates in United States, Americas, excluding the United States , Sweden, EMEA, excluding Sweden, and APAC. The company's business is divided into three operating segments. These segments are based on a geographical division and consist of the regions Americas (North and South America), EMEA (Europe, Middle East and Africa) and APAC (Asia and the Pacific).

Probi AB (OSTO:PROB) Headlines

No Headlines